Heart Tronics Inc (HRTT)

[TechKim]

Signalife Completes Phase One of Its Distribution Strategy
Monday April 16, 9:38 am ET
http://biz.yahoo.com/prnews/070416/nym095.html?.v=59

GREENVILLE, S.C., April 16 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News)
Signalife announces it has hired a new distribution organization for its Fidelity 100 product line. The group consists of independent distributor reps for cardiac rhythm management products (ICD's and pacemakers). The initial focus will be the Southern region from North Carolina to Texas, but additional representation is already under consideration in other areas of the country. The initial number of sales representatives will start at 25 and may increase to 50 before year end.



"This is a very exciting development for Signalife as the independent representatives are experienced and understand the significance of our technology and product. They have existing relationships with physicians and hospitals that mirror the desired call points for our company. We are pleased to complete phase one of this distribution channel, and look forward to results created by a professional sales force within the industry," stated Pamela Bunes, CEO of Signalife, Inc.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.